ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

GLEOSTINE
Head and neck cancer
Leukemias, lymphomas, and other hematologic cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

GLEOSTINE Rx

Generic Name and Formulations:
Lomustine 5mg, 10mg, 40mg, 100mg; caps.

Company:
NextSource Biotechnology, LLC

Therapeutic Use:

Indications for GLEOSTINE:

Treatment of patients with primary and metastatic brain tumors following appropriate surgery and/or radiotherapy.

Adults and Children:

Pretreat with antiemetics and give on empty stomach. Give one dose every 6 weeks. Previously untreated (as a single agent): 130mg/m2. Compromised bone marrow function: 100mg/m2. Combination with other myelosuppressive drugs: reduce dose accordingly. Subsequent doses: adjust according to hematologic response (see full labeling).

Warnings/Precautions:

Risk of delayed and cumulative myelosuppression leading to fatal infections and bleeding. Monitor CBCs weekly for at least 6 weeks after each dose; withhold each subsequent dose for >6 weeks if needed until platelets recover to ≥100,000/mm3 and leukocytes to ≥4000/mm3. Risk of overdosage (fatal toxicity); prescribe only 1 dose for every 6-week cycle. Monitor liver and renal function. Perform pulmonary function tests prior to and frequently during therapy; increased risk of pulmonary toxicity in patients with baseline <70% of the predicted Forced Vital Capacity or Carbon Monoxide Diffusing Capacity; permanently discontinue if pulmonary fibrosis occurs. Pregnancy. Use adequate contraception during therapy and for 2 weeks (females) or 3.5 months (males with female partners) after final dose. Nursing mothers: not recommended (during therapy and for 2 weeks after final dose).

Pharmacological Class:

Alkylating agent.

Adverse Reactions:

Delayed myelosuppression (thrombocytopenia, leukopenia), nausea, vomiting, stomatitis, alopecia; pulmonary toxicity, secondary malignancies, hepatotoxicity, nephrotoxicity.

Note:

Wear gloves when handling capsules. Formerly known under the brand name CeeNu.

How Supplied:

Caps—5

Indications for GLEOSTINE:

As a component of combination chemotherapy for the treatment of patients with Hodgkin's lymphoma whose disease has progressed following initial chemotherapy.

Adults and Children:

Pretreat with antiemetics and give on empty stomach. Give one dose every 6 weeks. Previously untreated (as a single agent): 130mg/m2. Compromised bone marrow function: 100mg/m2. Combination with other myelosuppressive drugs: reduce dose accordingly. Subsequent doses: adjust according to hematologic response (see full labeling).

Warnings/Precautions:

Risk of delayed and cumulative myelosuppression leading to fatal infections and bleeding. Monitor CBCs weekly for at least 6 weeks after each dose; withhold each subsequent dose for >6 weeks if needed until platelets recover to ≥100,000/mm3 and leukocytes to ≥4000/mm3. Risk of overdosage (fatal toxicity); prescribe only 1 dose for every 6-week cycle. Monitor liver and renal function. Perform pulmonary function tests prior to and frequently during therapy; increased risk of pulmonary toxicity in patients with baseline <70% of the predicted Forced Vital Capacity or Carbon Monoxide Diffusing Capacity; permanently discontinue if pulmonary fibrosis occurs. Pregnancy. Use adequate contraception during therapy and for 2 weeks (females) or 3.5 months (males with female partners) after final dose. Nursing mothers: not recommended (during therapy and for 2 weeks after final dose).

Pharmacological Class:

Alkylating agent.

Adverse Reactions:

Delayed myelosuppression (thrombocytopenia, leukopenia), nausea, vomiting, stomatitis, alopecia; pulmonary toxicity, secondary malignancies, hepatotoxicity, nephrotoxicity.

Note:

Wear gloves when handling capsules. Formerly known under the brand name CeeNu.

How Supplied:

Caps—5

Sign Up for Free e-newsletters